文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

核心技术专利：CN118964589B侵权必究

Tominaga T, Watanabe A, Hayashi H, Yanagihara Y, Koda A

Department of Pharmacology, Pharmaceuticals Research Center, Toyobo Co. Ltd., Shiga, Japan.

Gen Pharmacol. 1993 Mar;24(2):345-8. doi: 10.1016/0306-3623(93)90314-n.

The present study was carried out to investigate the effect of TYB-2285 (3,5-bis(acetoxyacetylamino)-4-chlorobenzonitrile) on histamine release from human basophils upon stimulation with anti-IgE in the presence/absence of recombinant interleukin 3 (rIL-3). 2. Histamine release was enhanced by the pretreatment of basophils with rIL-3 (0.3-10 U/ml) in 18 out of 22 subjects. 3. Histamine release in the presence of rIL-3 was inhibited by TYB-2285 and disodium cromoglycate (DSCG) in a dose-dependent manner (1-100 microM). 4. Histamine release in the absence of rIL-3 was not inhibited by TYB-2285 or DSCG at concentrations less than 1 mM. 5. From these results, it is suggested that TYB-2285 and DSCG might regulate allergic inflammation by the suppression of mediator release enhanced by IL-3.

本研究旨在探讨TYB - 2285（3,5 - 双（乙酰氧基乙酰氨基）- 4 - 氯苯腈）在存在/不存在重组白细胞介素3（rIL - 3）的情况下，对抗IgE刺激人嗜碱性粒细胞释放组胺的影响。2. 在22名受试者中的18名中，用rIL - 3（0.3 - 10 U/ml）预处理嗜碱性粒细胞可增强组胺释放。3. 在rIL - 3存在的情况下，组胺释放受到TYB - 2285和色甘酸二钠（DSCG）的剂量依赖性抑制（1 - 100 microM）。4. 在不存在rIL - 3的情况下，浓度低于1 mM的TYB - 2285或DSCG不会抑制组胺释放。5. 从这些结果表明，TYB - 2285和DSCG可能通过抑制IL - 3增强的介质释放来调节过敏性炎症。

Tominaga T, Watanabe A, Hayashi H, Yanagihara Y, Koda A

Department of Pharmacology, Pharmaceuticals Research Center, Toyobo Co. Ltd., Shiga, Japan.

Gen Pharmacol. 1993 Mar;24(2):345-8. doi: 10.1016/0306-3623(93)90314-n.

The present study was carried out to investigate the effect of TYB-2285 (3,5-bis(acetoxyacetylamino)-4-chlorobenzonitrile) on histamine release from human basophils upon stimulation with anti-IgE in the presence/absence of recombinant interleukin 3 (rIL-3). 2. Histamine release was enhanced by the pretreatment of basophils with rIL-3 (0.3-10 U/ml) in 18 out of 22 subjects. 3. Histamine release in the presence of rIL-3 was inhibited by TYB-2285 and disodium cromoglycate (DSCG) in a dose-dependent manner (1-100 microM). 4. Histamine release in the absence of rIL-3 was not inhibited by TYB-2285 or DSCG at concentrations less than 1 mM. 5. From these results, it is suggested that TYB-2285 and DSCG might regulate allergic inflammation by the suppression of mediator release enhanced by IL-3.

本研究旨在探讨TYB - 2285（3,5 - 双（乙酰氧基乙酰氨基）- 4 - 氯苯腈）在存在/不存在重组白细胞介素3（rIL - 3）的情况下，对抗IgE刺激人嗜碱性粒细胞释放组胺的影响。2. 在22名受试者中的18名中，用rIL - 3（0.3 - 10 U/ml）预处理嗜碱性粒细胞可增强组胺释放。3. 在rIL - 3存在的情况下，组胺释放受到TYB - 2285和色甘酸二钠（DSCG）的剂量依赖性抑制（1 - 100 microM）。4. 在不存在rIL - 3的情况下，浓度低于1 mM的TYB - 2285或DSCG不会抑制组胺释放。5. 从这些结果表明，TYB - 2285和DSCG可能通过抑制IL - 3增强的介质释放来调节过敏性炎症。